Opiate-dependent patients receiving methadone: How physicians should manage therapy

Canadian Family Physician

Volumn 42, Issue SEP., 1996, Pages 1769-1778

  Kahan, Meldon ^a,b,d   Sutton, Neal ^c,d  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c The College of Physicians and Surgeons of Ontario   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; COCAINE; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; PETHIDINE;

DETOXIFICATION; DRUG DEPENDENCE; DRUG USE; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; PATIENT COUNSELING; PREGNANCY; RELAPSE; REVIEW; SYMPTOMATOLOGY; URINALYSIS;

ADULT; COST OF ILLNESS; HUMANS; MALE; METHADONE; NARCOTICS; NEEDLE SHARING; OPIOID-RELATED DISORDERS; PATIENT EDUCATION; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE TREATMENT CENTERS; TREATMENT OUTCOME;

EID: 0029804403     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Fahlman R, Coutu JJ, editors. National drug intelligence estimates. Ottawa, Ont: Royal Canadian Mounted Police Publication, 1990.
2. Health Protection Branch, Health and Welfare Canada. The use of opioids in the management of opioid dependence. Ottawa, Ont: Health and Welfare Canada, 1992.
3. Judson BA, Ortiz S, Crouse L, Carney TM, Goldstein A. A follow-up study of heroin addicts five years after first admission to a methadone treatment program. Drug Alcohol Depend 1980;6:295-313.
4. Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiol 1974;100:101-11.
5. Dole VP, Joseph HJ. Long-term outcome of patients treated with methadone maintenance. Ann N Y Acad Sci 1978;311:181-9.
6. Newman RG. Double-blind comparison of methadone and placebo maintenance treatment of narcotic addicts in Hong Kong. Lancet 1979;8141:485-8.
7. Vanichseni S, Wongsuwan B, Choopanya K, Wongpanich K. A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: implications for prevention of HIV. Int J Addict 1991;26:1313-20.
8. Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedman P, Trigg HL. A randomized trial of an interim methadone maintenance clinic. Am J Public Health 1991;8(9):1185-91.
9. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969;280:1372-5.
10. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981;7:249-56.
11. Dole VP, Niswander M. Methadone maintenance treatment: a ten year perspective. JAMA 1976;235:2117-9.
12. Cushman R Methadone maintenance: long-term follow-up of detoxified patients. Ann N Y Acad Sci 1978;311:165-72.
13. Health and Welfare Canada. Drugs Directorate guidelines: the use of opioids in the management of opioid dependence. Ottawa, Ont: Health Protection Branch, 1992.
14. Gerstein DR, Lewin LS. Special report: treating drug problems. N Engl J Med 1990;323:844-8.
15. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman A, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York, NY: Pergamon Press, 1990:485-521.
16. Bell J, Seres V, Borwon P, Lewis J, Batey R. The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol Ther 1988;43:623-9.
17. Schwartz ML, Brcchbuhl AB, Kahl P, Miller MA, Selwyn, PA, Friedland GH. Pharmacokinetic interactions of Zidovudine and methadone in intravenous drug using patients with HIV infection. J Acquir Immune Defic Syndr 1992;5(6):619-26.
18. Ward J, Mattick R, Hall W. Key issues in methadone maintenance treatment. Kensington, Australia: New South Wales University Press Ltd, 1992.
19. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750-4.
20. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993;119:23-7.
21. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991;154(3):195-9.
22. Payte JT, Khuri ET. Principles of methadone dose determination. In: Parrino MW, editor. State methadone maintenance treatment guidelines. Bethesda, Md: Office for treatment improvement, Alcohol, Drug Abuse, and Mental Health Administration, Public Health Service, US Department of Health and Human Services, 1992:47-58.
23. Bell J, Hall W, Byth K. Changes in criminal activity after entering methadone maintenance. Br J Addict 1992;87:251-8.
24. Simpson DD. Treatment for drug abuse: follow-up outcomes and length of time spent. Arch Gen Psychiatry 1981;38:875-80.
25. Kanof PD, Aronson MJ, Ness R. Organic mood syndrome associated with detoxification from methadone maintenance. Am J Psychiatry 1993;150:423-8.
26. Senay EC, Dorus W, Goldberg F, Thornton W. Withdrawal from methadone maintenance: rate of withdrawal and expectation. Arch Gen Psychiatry 1977;34:361-7.
27. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. New York, NY: Springer-Verlag, 1991.
28. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brian CP. Counselling effects in methadone treatment. JAMA 1993;269:1953-9.
29. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511-8.
30. Finnegan LP. Management of pregnant drug-dependent women. Ann N Y Acad Sci 1978;311:135-46.
31. Finnegan LP, Recser DS, Connaughton JF Jr. The effects of maternal drug dependence on neonatal mortality. Drug Alcohol Depend 1977;2:131-40.
32. Kaltenbach K, Finnegan LP. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav Toxicol Teratol 1986;8:353-5.
33. Kaltenbach K, Finnegan LP. Perinatal and developmental outcome of infants exposed to methadone in-utero. Neurotoxicol Teratol 1987;9(4):311-3.
34. Doberczak TM, Thornton JC, Bernstein J, Kandall SR. Impact of maternal drug dependency on birth weight and head circumference of offspring. Am J Dis Child 1987;141:1163-7.
35. Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics 1985;75:269-74.
36. Chasnoff IJ, Hatcher R, Burns WJ. Polydrug and methadone-addicted newborns: a continuum of impairment? Pediatrics 1982;70:210-3.
37. Hans SL. Developmental consequences of prenatal exposure to methadone. Ann N Y Acad Sci 1989;562:195-207.
38. Marcus J, Hans SL, Jeremy RJ. Differential motor and state functioning in newborns of women on methadone. Neurobehav Toxicol Teratol 1982;4:459-62.
39. Marcus J, Hans SL, Jeremy RJ. Patterns of 1-day and 4-month motor functioning in infants of women on methadone. Neurobehav Toxicol Teratol 1982;4:473-6.
40. Strauss ME, Starr RH, Ostrea EM, Chavez CJ, Stryker JC. Behavioral concomitants of prenatal addiction to narcotics. Behav Pediatr 1976;89(5):842-6.
41. Coates RA, Rankin JG, Lamothe F, Arshinoff R, Raboud J, Millson ME, et al. Needle sharing behaviour among injection drug users (IDUs) in treatment in Montreal and Toronto, 1988-1989. Can J Public Health 1992;83(1):38-41.
42. Chaudhary RK, Mo T. Antibody to hepatitis C virus in risk groups in Canada. Can J Infect Dis 1992;3(1):27-9.
43. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alpha; a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
44. Lamothe F, Bruneau J, Coates R, Rankin JG, Soto J, Arshinoff R, et al. Seroprevalence of and risk factors for HIV-1 infection in injection drug users in Montreal and Toronto: a collaborative study. Can Med Assoc J 1993;149(7):945-51.
45. Cooper JR. Methadone treatment and acquired immunodeficiency syndrome. JAMA 1989;262:1664-8.
46. Brickner PW, Torres RA, Barnes M, Newman RG, Des Jarlais DC, Whalen DP, et al. Recommendations for control and prevention of human immunodeficiency virus (HIV) infection in intravenous drug users. Ann Intern Med 1989;110:833-7.
47. Novick DM, Joseph H, Croxson TS, Salsitz EA, Wang G, Richman BL, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990;150:97-9.